The Weight-Loss Drug Rivalry Heats Up as Another GLP-1 Pill Gains FDA Approval
The FDA has approved Foundayo, a second oral GLP-1 drug for weight loss, adding a new pill option to a market long dominated by injectable treatments.
The FDA has approved a second oral GLP-1 medication for weight loss, a drug called Foundayo that delivered an average of 27 pounds lost over 72 weeks in clinical trials. The approval marks a meaningful shift in how patients can access this class of drugs, which until recently was synonymous with weekly injections.
Foundayo joins Novo Nordisk’s oral semaglutide pill as the only GLP-1 options that don’t require a needle. For the millions of people who have avoided weight-loss drugs specifically because of the injection barrier, the growing pill market represents a real change in what’s available to them.
Details
GLP-1 receptor agonists work by mimicking a hormone that regulates appetite and blood sugar. The injectable versions, including semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound), have dominated headlines and prescriptions for the past few years. Oral versions have been harder to develop because the gut tends to break down these molecules before they can be absorbed effectively.
Foundayo’s trial results showed an average weight loss of 27 pounds over 72 weeks. That’s a meaningful number, though direct comparisons with injectable drugs are complicated because trials use different patient populations, dosing schedules, and durations. Scientific American’s reporting notes that the drug’s profile adds another data point to an increasingly crowded competitive space, but doesn’t position any single drug as a clear winner across all patients.
The approval comes at a time when Eli Lilly and Novo Nordisk are both pushing into oral formulations, and competition is intensifying not just on efficacy but on convenience, cost, and access. Foundayo enters a market where payers, employers, and pharmacy benefit managers are still sorting out how to handle GLP-1 coverage, which adds another layer of uncertainty for patients trying to figure out what they can actually afford.
It’s also worth noting that 72 weeks is just under a year and a half. Long-term data beyond that window, including what happens to weight after people stop taking the drug, is still being gathered and studied. That’s not unique to Foundayo; it’s a gap across most drugs in this class.
Why It Matters
For patients, having a pill option matters. Injection fatigue is real, and some people simply won’t start or stay on a drug that requires weekly self-injection. If oral GLP-1s can deliver comparable results to injectables for enough patients, the addressable population for this class of drugs grows substantially.
For the broader market, this approval signals that the oral GLP-1 race is no longer a one-horse competition. Novo Nordisk’s oral semaglutide got there first, but now there’s a second approved pill with its own efficacy data. That competition could eventually push prices down or prompt manufacturers to differentiate on formulation, side effect profiles, or dosing convenience.
From a regulatory standpoint, the FDA’s willingness to approve a second oral GLP-1 on the strength of its own trial data, rather than requiring head-to-head comparisons, reflects how this agency typically handles drugs in established classes. It approved the drug on its merits, not on whether it beats a competitor.
What’s Next
The immediate question is how quickly Foundayo reaches patients. Approval clears the regulatory hurdle, but manufacturing, insurance coverage decisions, and pharmacy stocking all take time. It’s not unusual for a newly approved drug to take months before it’s widely available at pharmacies or covered by most insurance plans.
Longer term, the oral GLP-1 category is likely to keep expanding. Several other compounds are in late-stage trials, and the appetite among both drug developers and patients isn’t showing signs of cooling off. Whether Foundayo carves out a significant share of that market depends heavily on pricing and how it performs in real-world use outside of controlled trials.
For anyone considering GLP-1 therapy, the practical advice from most clinicians remains the same: work with a healthcare provider to evaluate which option fits your specific situation, because what matters most is what you’ll actually take consistently and tolerate well.
Related Reading
Original Source
scientificamerican.com →